Homeostatic chemokines guide lymphoma cells to tumor growth-promoting niches within secondary lymphoid organs

Journal of Molecular Medicine

Volumn 90, Issue 11, 2012, Pages 1237-1245

  Höpken, Uta E ^a   Rehm, Armin ^a,b  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

B cell lymphoma; Homeostatic cytokines; Lymphoma stroma crosstalk; Microenvironment

Indexed keywords

B LYMPHOCYTE ANTIBODY; BAMINERCEPT; CHEMOKINE; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR5; CXCL13 CHEMOKINE; CYTOKINE; CYTOTOXIC AGENT; FOSTAMATINIB; HOMING RECEPTOR; IBRUTINIB; IDELALISIB; LYMPHOTOXIN; LYMPHOTOXIN BETA RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; PLERIXAFOR; SECONDARY LYMPHOID TISSUE CHEMOKINE; T 140; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1;

ARTICLE; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; B LYMPHOCYTE; CELL HOMING; CELL INTERACTION; CELL MIGRATION; CHRONIC LYMPHATIC LEUKEMIA; DENDRITIC CELL; FOLLICULAR DENDRITIC CELL; GASTRITIS; HEMATOLOGIC MALIGNANCY; HOMEOSTASIS; HUMAN; LARGE CELL LYMPHOMA; LEUKEMIA; LIVER CELL CARCINOMA; LYMPHOCYTE PROLIFERATION; LYMPHOID ORGAN; LYMPHOMA CELL; MACROPHAGE; MARGINAL ZONE LYMPHOMA; NONHUMAN; ORGANOGENESIS; RETICULUM CELL; RHEUMATOID ARTHRITIS; SECONDARY LYMPHOID ORGAN; STROMA CELL; SUPPRESSOR CELL; T CELL LEUKEMIA; T LYMPHOCYTE; TERTIARY LYMPHOID ORGAN; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR PROMOTION;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CELL COMMUNICATION; CHEMOKINES; CYTOKINES; HOMEOSTASIS; HUMANS; KINETICS; LYMPHOMA; LYMPHOMA, B-CELL; LYMPHOTOXIN-ALPHA; MICE; MODELS, BIOLOGICAL; NEOPLASMS; STROMAL CELLS; TUMOR MICROENVIRONMENT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84868113996     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-012-0906-z     Document Type: Article

References (83)

1. Lenz G, Staudt LM (2010) Aggressive lymphomas. N Engl J Med 362:1417-1429
2. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD et al (2010) Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 362:875-885
3. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J et al (2008) Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359:2313-2323
4. Mueller SN, Germain RN (2009) Stromal cell contributions to the homeostasis and functionality of the immune system. Nat Rev Immunol 9:618-629
5. Roozendaal R, Mebius RE (2011) Stromal cell-immune cell interactions. Annu Rev Immunol 29:23-43
6. Muller G, Lipp M (2003) Concerted action of the chemokine and lymphotoxin system in secondary lymphoid-organ development. Curr Opin Immunol 15:217-224
7. Muller G, Hopken UE, Lipp M (2003) The impact of CCR7 and CXCR5 on lymphoid organ development and systemic immunity. Immunol Rev 195:117-135
8. Ware CF (2005) Network communications: lymphotoxins, LIGHT, and TNF. Annu Rev Immunol 23:787-819
9. Muller G, Hopken UE, Stein H, Lipp M (2002) Systemic immunoregulatory and pathogenic functions of homeostatic chemokine receptors. J Leukoc Biol 72:1-8
10. Lopez-Giral S, Quintana NE, Cabrerizo M, Alfonso-Perez M, Sala-Valdes M, De Soria VG, Fernandez-Ranada JM, Fernandez-Ruiz E, Munoz C (2004) Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination. J Leukoc Biol 76:462-471
11. Mazzucchelli L, Blaser A, Kappeler A, Scharli P, Laissue JA, Baggiolini M, Uguccioni M (1999) BCA-1 is highly expressed in Helicobacter pylori-induced mucosa-associated lymphoid tissue and gastric lymphoma. J Clin Invest 104:R49-54
12. Kahnert A, Hopken UE, Stein M, Bandermann S, Lipp M, Kaufmann SH (2007) Mycobacterium tuberculosis triggers formation of lymphoid structure in murine lungs. J Infect Dis 195:46-54
13. Winter S, Loddenkemper C, Aebischer A, Rabel K, Hoffmann K, Meyer TF, Lipp M, Hopken UE (2010) The chemokine receptor CXCR5 is pivotal for ectopic mucosa-associated lymphoid tissue neogenesis in chronic Helicobacter pylori-induced inflammation. J Mol Med (Berl) 88:1169-1180
14. Forster R, Mattis AE, Kremmer E, Wolf E, Brem G, Lipp M (1996) A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell 87:1037-1047
15. Forster R, Schubel A, Breitfeld D, Kremmer E, Renner-Muller I, Wolf E, Lipp M (1999) CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99:23-33
16. Springer TA (1994) Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76:301-314
17. Butcher EC, Picker LJ (1996) Lymphocyte homing and homeostasis. Science 272:60-66
18. Jalkanen S, Reichert RA, Gallatin WM, Bargatze RF, Weissman IL, Butcher EC (1986) Homing receptors and the control of lymphocyte migration. Immunol Rev 91:39-60
19. Pals ST, de Gorter DJ, Spaargaren M (2007) Lymphoma dissemination: the other face of lymphocyte homing. Blood 110:3102-3111
20. Drillenburg P, Pals ST (2000) Cell adhesion receptors in lymphoma dissemination. Blood 95:1900-1910
21. Hopken UE, Foss HD, Meyer D, Hinz M, Leder K, Stein H, Lipp M (2002) Up-regulation of the chemokine receptor CCR7 in classical but not in lymphocyte-predominant Hodgkin disease correlates with distinct dissemination of neoplastic cells in lymphoid organs. Blood 99:1109-1116
22. Burger JA, Kipps TJ (2002) Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells. Leuk Lymphoma 43:461-466
23. Trentin L, Cabrelle A, Facco M, Carollo D, Miorin M, Tosoni A, Pizzo P, Binotto G, Nicolardi L, Zambello R et al (2004) Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas. Blood 104:502-508
24. Chunsong H, Yuling H, Li W, Jie X, Gang Z, Qiuping Z, Qingping G, Kejian Z, Li Q, Chang AE et al (2006) CXC chemokine ligand 13 and CC chemokine ligand 19 cooperatively render resistance to apoptosis in B cell lineage acute and chronic lymphocytic leukemia CD23 + CD5+ B cells. J Immunol 177:6713-6722
25. Husson H, Freedman AS, Cardoso AA, Schultze J, Munoz O, Strola G, Kutok J, Carideo EG, De Beaumont R, Caligaris-Cappio F et al (2002) CXCL13 (BCA-1) is produced by follicular lymphoma cells: role in the accumulation of malignant B cells. Br J Haematol 119:492-495
26. Rodig SJ, Jones D, Shahsafaei A, Dorfman DM (2002) CCR6 is a functional chemokine receptor that serves to identify select B-cell non-Hodgkin's lymphomas. Hum Pathol 33:1227-1233
27. Rehm A, Anagnostopoulos I, Gerlach K, Broemer M, Scheidereit C, Johrens K, Hubler M, Hetzer R, Stein H, Lipp M, Dorken B, Hopken UE (2009) Identification of a chemokine receptor profile characteristic for mediastinal large B-cell lymphoma. Int J Cancer 125:2367-2374
28. Kuppers R (2009) The biology of Hodgkin's lymphoma. Nat Rev Cancer 9:15-27
29. Yang J, Wang S, Zhao G, Sun B (2011) Effect of chemokine receptors CCR7 on disseminated behavior of human T cell lymphoma: clinical and experimental study. J Exp Clin Cancer Res 30:51
30. Carver BS, Pandolfi PP (2006) Mouse modeling in oncologic preclinical and translational research. Clin Cancer Res 12:5305-5311
31. Tarantul VZ (2004) Transgenic mice as an in vivo model of lymphomagenesis. Int Rev Cytol 236:123-180
32. Bernardi R, Grisendi S, Pandolfi PP (2002) Modelling haematopoietic malignancies in the mouse and therapeutical implications. Oncogene 21:3445-3458
33. Seldin DC (1995) New models of lymphoma in transgenic mice. Curr Opin Immunol 7:665-673
34. Dierks C, Grbic J, Zirlik K, Beigi R, Englund NP, Guo GR, Veelken H, Engelhardt M, Mertelsmann R, Kelleher JF et al (2007) Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat Med 13:944-951
35. Refaeli Y, Young RM, Turner BC, Duda J, Field KA, Bishop JM (2008) The B cell antigen receptor and overexpression of MYC can cooperate in the genesis of B cell lymphomas. PLoS Biol 6:e152
36. Cyster JG (2010) B cell follicles and antigen encounters of the third kind. Nat Immunol 11:989-996
37. Langdon WY, Harris AW, Cory S, Adams JM (1986) The c-myc oncogene perturbs B lymphocyte development in E-mu-myc transgenic mice. Cell 47:11-18
38. Reimann M, Loddenkemper C, Rudolph C, Schildhauer I, Teichmann B, Stein H, Schlegelberger B, Dorken B, Schmitt CA (2007) The Myc-evoked DNA damage response accounts for treatment resistance in primary lymphomas in vivo. Blood 110:2996-3004
39. Reimann M, Schmitt CA, Lee S (2011) Non-cell-autonomous tumor suppression: oncogene-provoked apoptosis promotes tumor cell senescence via stromal crosstalk. J Mol Med (Berl) 89:869-875
40. Maclean KH, Dorsey FC, Cleveland JL, Kastan MB (2008) Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. J Clin Invest 118:79-88
41. Ruddell A, Mezquita P, Brandvold KA, Farr A, Iritani BM (2003) B lymphocyte-specific c-Myc expression stimulates early and functional expansion of the vasculature and lymphatics during lymphomagenesis. Am J Pathol 163:2233-2245
42. Rehm A, Mensen A, Schradi K, Gerlach K, Wittstock S, Winter S, Buchner G, Dorken B, Lipp M, Hopken UE (2011) Cooperative function of CCR7 and lymphotoxin in the formation of a lymphoma-permissive niche within murine secondary lymphoid organs. Blood 118:1020-1033
43. Buonamici S, Trimarchi T, Ruocco MG, Reavie L, Cathelin S, Mar BG, Klinakis A, Lukyanov Y, Tseng JC, Sen F et al (2009) CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature 459:1000-1004
44. Bajenoff M, Egen JG, Koo LY, Laugier JP, Brau F, Glaichenhaus N, Germain RN (2006) Stromal cell networks regulate lymphocyte entry, migration, and territoriality in lymph nodes. Immunity 25:989-1001
45. Carbone A, Gloghini A, Gruss HJ, Pinto A (1995) CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease. Am J Pathol 147:912-922
46. Pangault C, Ame-Thomas P, Ruminy P, Rossille D, Caron G, Baia M, De Vos J, Roussel M, Monvoisin C, Lamy T et al (2010) Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent T(FH)-B cell axis. Leukemia 24:2080-2089
47. Dubois B, Vanbervliet B, Fayette J, Massacrier C, Van Kooten C, Briere F, Banchereau J, Caux C (1997) Dendritic cells enhance growth and differentiation of CD40-activated B lymphocytes. J Exp Med 185:941-951
48. Craxton A, Magaletti D, Ryan EJ, Clark EA (2003) Macrophage- and dendritic cell-dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF. Blood 101:4464-4471
49. Mueller CG, Boix C, Kwan WH, Daussy C, Fournier E, Fridman WH, Molina TJ (2007) Critical role of monocytes to support normal B cell and diffuse large B cell lymphoma survival and proliferation. J Leukoc Biol 82:567-575
50. He B, Chadburn A, Jou E, Schattner EJ, Knowles DM, Cerutti A (2004) Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol 172:3268-3279
51. Ogden CA, Pound JD, Batth BK, Owens S, Johannessen I, Wood K, Gregory CD (2005) Enhanced apoptotic cell clearance capacity and B cell survival factor production by IL-10-activated macrophages: implications for Burkitt's lymphoma. J Immunol 174:3015-3023
52. Allavena P, Sica A, Solinas G, Porta C, Mantovani A (2008) The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 66:1-9
53. Gabrilovich D (2004) Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 4:941-952
54. Zou W (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6:295-307
55. Fricke I, Gabrilovich DI (2006) Dendritic cells and tumor microenvironment: a dangerous liaison. Immunol Invest 35:459-483
56. Norian LA, Rodriguez PC, O'Mara LA, Zabaleta J, Ochoa AC, Cella M, Allen PM (2009) Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism. Cancer Res 69:3086-3094
57. Aspord C, Pedroza-Gonzalez A, Gallegos M, Tindle S, Burton EC, Su D, Marches F, Banchereau J, Palucka AK (2007) Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med 204:1037-1047
58. Janikashvili N, Bonnotte B, Katsanis E, Larmonier N The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance. Clin Dev Immunol 2011: 430394
59. Lin Y, Gustafson MP, Bulur PA, Gastineau DA, Witzig TE, Dietz AB (2010) Immunosuppressive CD14 + HLA-DR(low)/-monocytes in B-cell non-Hodgkin lymphoma. Blood 117:872-881
60. Maby-El Hajjami H, Ame-Thomas P, Pangault C, Tribut O, DeVos J, Jean R, Bescher N, Monvoisin C, Dulong J, Lamy T et al (2009) Functional alteration of the lymphoma stromal cell niche by the cytokine context: role of indoleamine-2,3 dioxygenase. Cancer Res 69:3228-3237
61. Ame-Thomas P, Maby-El Hajjami H, Monvoisin C, Jean R, Monnier D, Caulet-Maugendre S, Guillaudeux T, Lamy T, Fest T, Tarte K (2007) Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis. Blood 109:693-702
62. Krampera M (2011) Mesenchymal stromal cell 'licensing': a multistep process. Leukemia 25:1408-1414
63. Chiorazzi N, Rai KR, Ferrarini M (2005) Chronic lymphocytic leukemia. N Engl J Med 352:804-815
64. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F (2009) The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 114:3367-3375
65. Lagneaux L, Delforge A, Bron D, De Bruyn C, Stryckmans P (1998) Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 91:2387-2396
66. Vincent AM, Cawley JC, Burthem J (1996) Integrin function in chronic lymphocytic leukemia. Blood 87:4780-4788
67. Luther SA, Tang HL, Hyman PL, Farr AG, Cyster JG (2000) Coexpression of the chemokines ELC and SLC by T zone stromal cells and deletion of the ELC gene in the plt/plt mouse. Proc Natl Acad Sci USA 97:12694-12699
68. Haybaeck J, Zeller N, Wolf MJ, Weber A, Wagner U, Kurrer MO, Bremer J, Iezzi G, Graf R, Clavien PA et al (2009) A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 16:295-308
69. Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M (2010) B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 464:302-305
70. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860-867
71. Browning JL (2008) Inhibition of the lymphotoxin pathway as a therapy for autoimmune disease. Immunol Rev 223:202-220
72. Wolf MJ, Seleznik GM, Zeller N, Heikenwalder M (2010) The unexpected role of lymphotoxin beta receptor signaling in carcinogenesis: from lymphoid tissue formation to liver and prostate cancer development. Oncogene 29:5006-5018
73. Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S (2010) From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 10:37-50
74. Burger JA (2011) Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematol Am Soc Hematol Educ Program 2011:96-103
75. Burger JA (2010) Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): from understanding the basics towards therapeutic targeting. Semin Cancer Biol 20:424-430
76. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP et al (2010) Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115:2578-2585
77. Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA et al (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 107:13075-13080
78. Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, Byrd JC, Tyner JW, Loriaux MM, Deininger M et al (2011) CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 117:591-594
79. Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda WG, Gandhi V, Burger JA (2009) B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 114:1029-1037
80. Hu Y, Gale M, Shields J, Garron C, Swistak M, Nguyen TH, Jacques G, Fogle R, Siders W, Kaplan J (2012) Enhancement of the anti-tumor activity of therapeutic monoclonal antibodies by CXCR4 antagonists. Leuk Lymphoma 53:130-138
81. O'Callaghan K, Lee L, Nguyen N, Hsieh MY, Kaneider NC, Klein AK, Sprague K, Van Etten RA, Kuliopulos A, Covic L (2012) Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia. Blood 119:1717-1725
82. Forster R, Davalos-Misslitz AC, Rot A (2008) CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol 8:362-371
83. Winter S, Rehm A, Wichner K, Scheel T, Batra A, Siegmund B, Berek C, Lipp M, Hopken UE (2011) Manifestation of spontaneous and early autoimmune gastritis in CCR7-deficient mice. Am J Pathol 179:754-765